There is a significant burden of disease among individuals with CHD; the disease affects quality of life, disability, life expectancy, medical spending, chronic disease, as well as employment and education outcomes.
The COVID-19 pandemic has imposed significant and far-reaching health and economic costs. This white paper models and monetizes the health-related benefits of two hypothetical treatments administered either before or after hospitalization; both generate substantial value.
This study provides the first comparison of trends in dementia prevalence in the U.S. population using 3 different dementia ascertainments/data sources. They found there are still substantial differences across measures in dementia prevalence among Blacks and Hispanics.